AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30032828
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (A) with radiation dose of 68 Gy
Trial: 25316134
Drug: Biophysical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biophysical therapy (Med Select 729)
Trial: 16447669
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group given 20 mL of Shenmai Injectio intravenously for 6 days
Trial: 8248611
Drug: Propofol (1-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1-1.5 mg/kg) administered before retrobulbar anesthesia
Trial: 2935243
Drug: Hepatic resection
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic resection plus continuous hepatic artery infusion (CHAI) of fluorodeoxyuridine (FUDR)
Trial: 22575076
Drug: Baker's yeast
RxNorm normalized name: Baker's yeast proteinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baker's yeast β-glucan (250 mg/d)
Trial: 21910332
Drug: Needling +
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needling + Fluoxetine
Trial: 17391911
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for fear of flying, 8 sessions
Trial: 12679475
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (n=8)
Trial: 12679475
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=8)
Trial: 8919832
Drug: Ketorolac 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.4 mg/kg administered 10 min before induction
Trial: 8919832
Drug: Ketorolac 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.4 mg/kg administered 5 min after decollement of nasal septum
Trial: 6117988
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bunitrolol (Stresson)
Trial: 6117988
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bunitrolol (Stresson)
Trial: 31642408
Drug: Neurological music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological music therapy intervention for 3 months (AB group)
Trial: 31642408
Drug: Neurological music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological music therapy intervention for 3 months (BA group)
Trial: 31396693
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) subcutaneous administration
Trial: 28276192
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of medroxyprogesterone acetate (MPA) per day
Trial: 28276192
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of medroxyprogesterone acetate (MPA) per day
Trial: 20957399
Drug: Parecoxib 80
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 80 mg daily i.v.
Trial: 20957399
Drug: Lornoxicam 16
RxNorm normalized name: Lornoxicam 16 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 16 mg daily i.v.
Trial: 20957399
Drug: Diclofenac 150
RxNorm normalized name: diclofenac sodium 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 150 mg daily i.m.
Trial: 18795893
Drug: Oral antioxidants
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidants (vitamins C and E, and alpha‐lipoic acid)
Trial: 18795893
Drug: Antioxidant administration
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant administration after exercise training
Trial: 16970165
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg once a day for 8 weeks
Trial: 15137556
Drug: Music-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-based exercise programme (daily physical exercises supported by music for 30 min/session for three months)
Trial: 15137556
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily conversation for the same duration)
Trial: 9314469
Drug: Vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (125 mg perorally four times daily for 7 days)
Trial: 29294360
Drug: Ciclesonide 160
RxNorm normalized name: CICLESONIDE 160MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 160 μg once-daily
Trial: 29294360
Drug: Glycopyrronium 44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium 44 μg once-daily
Trial: 28872637
Drug: 24 healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 healthy controls before and after 4 weeks of no treatment
Trial: 17416954
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% proparacaine
Trial: 12749495
Drug: Control (compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (compounds without ITNs)
Trial: 8624657
Drug: 585-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585-nm pulsed dye laser treatment with 10-mm spot size and 3.0 J/cm2 fluence
Trial: 8624657
Drug: 585-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585-nm pulsed dye laser treatment (all protocols)
Trial: 8624657
Drug: 585-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585-nm pulsed dye laser treatment
Trial: 23153036
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 20% essential oil of black pepper in aloe vera gel
Trial: 19238088
Drug: Venlafaxine 225-375
RxNorm normalized name: venlafaxine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 225-375 mg/day
Trial: 17989532
Drug: Allergen specific
RxNorm normalized name: Allergen specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen specific immunotherapy
Trial: 16107993
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tenofovir disoproxil fumarate and full-dose didanosine
Trial: 16107993
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or neither of the agents (Control)
Trial: 7657105
Drug: Cyclosporine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (5 mg.kg‐1.day‐1)
Trial: 4923930
Drug: Medazepam 10
RxNorm normalized name: medazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medazepam 10 mg three times a day
Trial: 4923930
Drug: Amylobarbitone 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylobarbitone 60 mg three times a day
Trial: 31978238
Drug: Life review
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life review (LR) therapy provided by family caregivers
Trial: 25921522
Drug: Physician-directed patient
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-directed patient self-management therapeutic strategy based on left atrial pressure (LAP) measured twice daily by an implantable sensor
Trial: 19786657
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with leucovorin and fluorouracil after six cycles of mFOLFOX7 (arm 1)
Trial: 19786657
Drug: Chemotherapy-free interval
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-free interval (CFI) after six cycles of mFOLFOX7 (arm 2)
Trial: 17482432
Drug: Quetiapine (50-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (50-400 mg/day)
Trial: 17482432
Drug: Risperidone (0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5-2 mg/day)
Trial: 7965482
Drug: Rice-based ORS
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based ORS solution
Trial: 7965482
Drug: Standard glucose-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucose-based ORS solution
Trial: 3655273
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g q.i.d. for 8 weeks
Trial: 3655273
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg q.i.d. for 8 weeks
Trial: 26311735
Drug: Cognitive-behavioral therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy-based techniques targeting grief, loss, and change
Trial: 23252525
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg if weight ≥30 kg or 12 mg/kg if weight <30 kg) given intravenously every 2 weeks for 12 weeks
Trial: 20517827
Drug: Magnesium (50
RxNorm normalized name: magnesium gluconate 27 mg magnesium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (50 mg/kg bolus followed by 10 mg/kg/h for 24 hours)
Trial: 17991790
Drug: Added external
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Added external dead space (DS) of 200, 400, and 600 ml
Trial: 16268802
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel (all doses)
Trial: 12132061
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg + saline (FB)
Trial: 12132061
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg + epinephrine 100 microg (FBE)
Trial: 10072142
Drug: CGP 56697
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 56697 (4 x 4 tablets each containing 20 mg of artemether and 120 mg of benflumetol, given at 0, 8, 24, and 48 hr)
Trial: 10072142
Drug: Mefloquine (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (three tablets of 250 mg at initial diagnosis, followed by two tablets of 250 mg at 8 hr)
Trial: 7487854
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of information (about oral health and dental treatment)
Trial: 26934969
Drug: MOUTh intervention
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOUTh intervention (Managing Oral Hygiene Using Threat Reduction Strategies)
Trial: 24201414
Drug: 60 ml/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml/h infusion of 30 mg nefopam
Trial: 24201414
Drug: 120 ml/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 ml/h infusion of 30 mg nefopam
Trial: 24201414
Drug: 180 ml/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 ml/h infusion of 30 mg nefopam
Trial: 17805582
Drug: Dipyrone 500
RxNorm normalized name: dipyrone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 500 mg PO every 6 h
Trial: 16607045
Drug: Basal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal treatment (aspirin 162 mg + cilostazol 200 mg/day)
Trial: 16607045
Drug: ACEI (basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (basal treatment + quinapril 10 mg or perindopril 4 mg/day)
Trial: 16607045
Drug: ARB (basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (basal treatment + losartan 50 mg/day)
Trial: 12943062
Drug: Broad-spectrum beta-lactam
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum beta-lactam antibiotics (Control)
Trial: 1507816
Drug: Cordarone (intravenous)
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cordarone (intravenous)
Trial: 1507816
Drug: Disopyramide (intravenous)
DrugBank: Disopyramide (DB00280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disopyramide (intravenous)
Trial: 1507816
Drug: Ajmaline (intravenous)
RxNorm normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline (intravenous)
Trial: 1507816
Drug: Verapamil (intravenous)
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (intravenous)
Trial: 1507816
Drug: Novocaine amide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novocaine amide (intravenous)
Trial: 1507816
Drug: Ethacizin (intravenous)
RxNorm normalized name: ethacizine
DrugBank: Ethacizine (DB13645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethacizin (intravenous)
Trial: 1507816
Drug: Quinidine (oral)
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine (oral)
Trial: 1507816
Drug: Kinilentin (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinilentin (oral)
Trial: 1507816
Drug: Disopyramide (oral)
DrugBank: Disopyramide (DB00280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disopyramide (oral)
Trial: 1507816
Drug: Propranolol (oral)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (oral)
Trial: 1507816
Drug: Mexitil (oral)
RxNorm normalized name: mexiletine hydrochloride Oral Capsule [Mexitil]
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexitil (oral)
Trial: 1507816
Drug: Overall efficacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall efficacy of antiarrhythmic therapy
Trial: 6343416
Drug: Naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.8 mg/h)
Trial: 6343416
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (6.5 ml/h)
Trial: 24569914
Drug: Z-100 at
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-100 at 0.2 µg (Z)
Trial: 23122972
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine dosing strategies (80% of usual dose, call physician for dose, refer to dosing table)
Trial: 23122972
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus bolus group (dosing table strategy)
Trial: 23122972
Drug: Insulin glargine‐only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine‐only group
Trial: 23122972
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus bolus group
Trial: 7032305
Drug: Blank rotating
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank rotating disk (same duration as treatment group)
Trial: 7032305
Drug: Weekly acuity
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly acuity evaluation without treatment (second control group)
Trial: 30665198
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy (MT) directed at the right-side ankle and foot
Trial: 30665198
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (CONTROL group)
Trial: 22134226
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (primarily vapocoolant spray)
Trial: 19138437
Drug: High fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fish oil (HFO) meal (2.2 g fish oil)
Trial: 19138437
Drug: Reference (REF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference (REF) meal (0.3 g fish oil)
Trial: 15539706
Drug: Thiotepa (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotepa (15 mg on days 1, 3, and 5 after percutaneous pericardiocentesis)
Trial: 11394556
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi exercise program (6 months, twice per week for 60 min)
Trial: 9480997
Drug: beclomethasone three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclomethasone three times daily
Trial: 9480997
Drug: theophylline twice
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: theophylline twice daily
Trial: 7818840
Drug: Conventional antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive therapy (diuretics or beta-blockers)
Trial: 30980399
Drug: Sorafenib (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (lower dose)
Trial: 30980399
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxychloroquine and sorafenib
Trial: 23256574
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch 1 - 3 mg/24 h
Trial: 18438227
Drug: Pre-exercise energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exercise energy supplement (combination of branched chain amino acids, creatine, taurine, caffeine, and glucuronolactone)
Trial: 18438227
Drug: Pre-exercise energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exercise energy supplement
Trial: 12907538
Drug: Sequential i.v./po
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential i.v./po moxifloxacin monotherapy (400 mg qd)
Trial: 12907538
Drug: i.v./po co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v./po co-amoxiclav (1.2 g i.v./625 mg po tid) with or without clarithromycin (500 mg bid)
Trial: 10200750
Drug: Enhanced acute-phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced acute-phase treatment for depression
Trial: 10200750
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment for depression
Trial: 7634752
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of insulin-like growth factor I (30 micrograms h-1 kg-1) and insulin (0.23 nmol h-1 kg-1)
Trial: 7634752
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of insulin-like growth factor I (5 micrograms h-1 kg-1) and insulin (0.04 nmol h-1 kg-1)
Trial: 2694482
Drug: Mefloquine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine alone (250 mg/week)
Trial: 2694482
Drug: Mefloquine, sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine, sulfadoxine (500 mg/week), and pyrimethamine (25 mg/week) (MSP)
Trial: 793186
Drug: Ketoprofen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (2 X 50 mg daily)
Trial: 793186
Drug: Phenylbutazone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (2 X 300 mg daily)
Trial: 29738183
Drug: Lamiophlomis Rotata
RxNorm normalized name: Phlomoides rotata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid for 4 weeks
Trial: 29738183
Drug: Lamiophlomis Rotata
RxNorm normalized name: Phlomoides rotata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid after 4 weeks of treatment
Trial: 29738183
Drug: Tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd after 4 weeks of treatment
Trial: 21441550
Drug: Etanercept (TNF-α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (TNF-α inhibitor)
Trial: 21441550
Drug: Infliximab (TNF-α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (TNF-α inhibitor)
Trial: 15187323
Drug: 308-nm excimer
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 308-nm excimer laser treatment with different initial UV doses, treated twice a week for up to 30 sessions.
Trial: 15187323
Drug: 308-nm excimer
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 308-nm excimer laser treatment for acral and joint areas.
Trial: 11502230
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g glucose drink
Trial: 11502230
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g glucose drink (informed)
Trial: 11502230
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g glucose drink (misinformed)
Trial: 8064736
Drug: Zinc acexamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc acexamate (ZAC) 300 mg